|
1
|
Linardic CM: PAX3-FOXO1 fusion gene in
rhabdomyosarcoma. Cancer Lett. 270:10–18. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sorensen PH, Lynch JC, Qualman SJ, et al:
PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in
alveolar rhabdomyosarcoma: a report from the Children’s Oncology
Group. J Clin Oncol. 20:2672–2679. 2002.PubMed/NCBI
|
|
3
|
Stevens MC: Treatment for childhood
rhabdomyosarcoma: the cost of cure. Lancet Oncol. 6:77–84. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Scrable HJ, Witte DP, Lampkin BC and
Cavenee WK: Chromosomal localization of the human rhabdomyosarcoma
locus by mitotic recombination mapping. Nature. 329:645–647. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Visser M, Sijmons C, Bras J, et al:
Allelotype of pediatric rhabdomyosarcoma. Oncogene. 15:1309–1314.
1997. View Article : Google Scholar
|
|
6
|
Davis RJ and Barr FG: Fusion genes
resulting from alternative chromosomal translocations are
overexpressed by gene-specific mechanisms in alveolar
rhabdomyosarcoma. Proc Natl Acad Sci USA. 94:8047–8051. 1997.
View Article : Google Scholar
|
|
7
|
Du S, Lawrence EJ, Strzelecki D, Rajput P,
Xia SJ, Gottesman DM and Barr FG: Co-expression of alternatively
spliced forms of PAX3, PAX7, PAX3-FKHR and PAX7-FKHR with distinct
DNA binding and transactivation properties in rhabdomyosarcoma. Int
J Cancer. 115:85–92. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kelly KM, Womer RB, Sorensen PHB, Xiong QB
and Barr FG: Common and variant gene fusions predict distinct
clinical phenotypes in rhabdomyosarcoma. J Clin Oncol.
15:1831–1836. 1997.PubMed/NCBI
|
|
9
|
Anderson J, Gordon T, McManus A, et al:
Detection of the PAX3-FKHR fusion gene in paediatric
rhabdomyosarcoma: a reproducible predictor of outcome? Br J Cancer.
85:831–835. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Khan J, Bittner ML, Saal LH, et al: cDNA
microarrays detect activation of a myogenic transcription program
by the PAX3-FKHR fusion oncogene. Proc Natl Acad Sci USA.
96:13264–13269. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wachtel M, Dettling M, Koscielniak E, et
al: Gene expression signatures identify rhabdomyosarcoma subtypes
and detect a novel t(2;2)(q35;q23) translocation fusing PAX3 to
NCOA1. Cancer Res. 64:5539–5545. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wachtel M, Runge T, Leuschner I, et al:
Subtype and prognostic classification of rhabdomyosarcoma by
immunohistochemistry. J Clin Oncol. 24:816–822. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Davicioni E, Finckenstein FG, Shahbazian
V, Buckley JD, Triche TJ and Anderson MJ: Identification of a
PAX-FKHR gene expression signature that defines molecular classes
and determines the prognosis of alveolar rhabdomyosarcoma. Cancer
Res. 66:6936–6946. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
De Pittà C, Tombolan L, Albiero G, et al:
Gene expression profiling identifies potential relevant genes in
alveolar rhabdomyosarcoma pathogenesis and discriminates PAX3-FKHR
positive and negative tumors. Int J Cancer. 118:2772–2781.
2006.
|
|
15
|
Laé M, Ahn EH, Mercado GE, et al: Global
gene expression profiling of PAX-FKHR fusion-positive alveolar and
PAX-FOXO1 fusion-negative embryonal rhabdomyosarcomas. J Pathol.
212:143–151. 2007.PubMed/NCBI
|
|
16
|
Mercado GE, Xia SJ, Zhang C, et al:
Identification of PAX3-FKHR-regulated genes differentially
expressed between alveolar and embryonal rhabdomyosarcoma: focus on
MYCN as a biologically relevant target. Genes Chromosomes Cancer.
47:510–520. 2008. View Article : Google Scholar
|
|
17
|
Barr FG, Smith LM, Lynch JC, Strzelecki D,
Parham DM, Qualman SJ and Breitfeld PP: Examination of gene fusion
status in archival samples of alveolar rhabdomyosarcoma entered on
the Intergroup Rhabdomyosarcoma Study-III trial: a report from the
Children’s Oncology Group. J Mol Diagn. 8:202–208. 2006.PubMed/NCBI
|
|
18
|
Bennicelli JL, Edwards RH and Barr FG:
Mechanism for transcriptional gain of function resulting from
chromosomal translocation in alveolar rhabdomyosarcoma. Proc Natl
Acad Sci USA. 93:5455–5459. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tomescu O, Xia SJ, Strezlecki D,
Bennicelli JL, Ginsberg J, Pawel B and Barr FG: Inducible
short-term and stable long-term cell culture systems reveal that
the PAX3-FKHR fusion oncoprotein regulates CXCR4, PAX3, and PAX7
expression. Lab Invest. 84:1060–1070. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xia SJ and Barr FG: Analysis of the
transforming and growth suppressive activities of the PAX3-FKHR
oncoprotein. Oncogene. 23:6864–6871. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xia SJ, Rajput P, Strzelecki DM and Barr
FG: Analysis of genetic events that modulate the oncogenic and
growth suppressive activities of the PAX3-FKHR fusion oncoprotein.
Lab Invest. 87:318–325. 2007.PubMed/NCBI
|
|
22
|
Littlewood TD, Hancock DC, Danielian PS,
Parker MG and Evan GI: A modified oestrogen receptor ligand-binding
domain as an improved switch for the regulation of heterologous
proteins. Nucleic Acids Res. 23:1686–1690. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tusher VG, Tibshirani R and Chu G:
Significance analysis of microarrays applied to the ionizing
radiation response. Proc Natl Acad Sci USA. 98:5116–5121. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang da W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009.PubMed/NCBI
|
|
25
|
Ahn EH and Schroeder JJ: Sphinganine
causes early activation of JNK and p38 MAPK and inhibition of AKT
in HT-29 human colon cancer cells. Anticancer Res. 26:121–127.
2006.PubMed/NCBI
|
|
26
|
Tonin PN, Scrable H, Shimada H and Cavenee
WK: Muscle-specific gene expression in rhabdomyosarcomas and stages
of human fetal skeletal muscle development. Cancer Res.
51:5100–5106. 1991.PubMed/NCBI
|
|
27
|
Tapscott SJ, Thayer MJ and Weintraub H:
Deficiency in rhabdomyosarcomas of a factor required for MyoD
activity and myogenesis. Science. 259:1450–1453. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ren YX, Finckenstein FG, Abdueva DA, et
al: Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar
rhabdomyosarcomas by cooperating with secondary mutations. Cancer
Res. 68:6587–6597. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Graf Finckenstein F, Shahbazian V,
Davicioni E, Ren YX and Anderson MJ: PAX-FKHR function as pangenes
by simultaneously inducing and inhibiting myogenesis. Oncogene.
27:2004–2014. 2008.PubMed/NCBI
|
|
30
|
Sun J, Kamei CN, Layne MD, Jain MK, Liao
JK, Lee ME and Chin MT: Regulation of myogenic terminal
differentiation by the hairy-related transcription factor CHF2. J
Biol Chem. 276:18591–18596. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Epstein JA, Lam P, Jepeal L, Maas RL and
Shapiro DN: Pax3 inhibits myogenic differentiation of cultured
myoblast cells. J Biol Chem. 270:11719–11722. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ebauer M, Wachtel M, Niggli FK and Schäfer
BW: Comparative expression profiling identifies an in vivo target
gene signature with TFAP2B as a mediator of the survival function
of PAX3/FKHR. Oncogene. 26:7267–7281. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kikuchi K, Tsuchiya K, Otabe O, et al:
Effects of PAX3-FKHR on malignant phenotypes in alveolar
rhabdomyosarcoma. Biochem Biophys Res Commun. 365:568–574. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Collins MH, Zhao H, Womer RB and Barr FG:
Proliferative and apoptotic differences between alveolar
rhabdomyosarcoma subtypes: a comparative study of tumors containing
PAX3-FKHR or PAX7-FKHR gene fusions. Med Pediatr Oncol. 37:83–89.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Anderson J, Ramsay A, Gould S and
Pritchard-Jones K: PAX3-FKHR induces morphological change and
enhances cellular proliferation and invasion in rhabdomyosarcoma.
Am J Pathol. 159:1089–1096. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bernasconi M, Remppis A, Fredericks WJ,
Rauscher FJ III and Schäfer BW: Induction of apoptosis in
rhabdomyosarcoma cells through down-regulation of PAX proteins.
Proc Natl Acad Sci USA. 93:13164–13169. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ayyanathan K, Fredericks WJ, Berking C,
Herlyn M, Balakrishnan C, Gunther E and Rauscher FJ III:
Hormone-dependent tumor regression in vivo by an inducible
transcriptional repressor directed at the PAX3-FKHR oncogene.
Cancer Res. 60:5803–5814. 2000.PubMed/NCBI
|
|
38
|
Xia SJ, Holder DD, Pawel BR, Zhang C and
Barr FG: High expression of the PAX3-FKHR oncoprotein is required
to promote tumorigenesis of human myoblasts. Am J Pathol.
175:2600–2608. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen B, Athanasiou M, Gu Q and Blair DG:
Drm/Gremlin transcriptionally activates p21(Cip1) via a novel
mechanism and inhibits neoplastic transformation. Biochem Biophys
Res Commun. 295:1135–1141. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bialik S and Kimchi A: DAP-kinase as a
target for drug design in cancer and diseases associated with
accelerated cell death. Semin Cancer Biol. 14:283–294. 2004.
View Article : Google Scholar : PubMed/NCBI
|
